Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of GSK2556286 in Healthy Adults
NCT04472897Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GSK2556286 in Tuberculosis (TB) (4 arms), sponsored by GSK. Primary endpoints: Number of participants with any serious adverse events (SAEs) and non-SAEs, Plasma concentrations of GSK2556286 at Day 14 and 5 more. Started Oct 2020; status: terminated.
02
Drugs
GSK2556286
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04472897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472897.